Drugs / AJ302-IM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06625541 | Jun 2024 → Aug 2025 | — | AnnJi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AJ302-IM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625541 ↗ |
| Route | Intramuscular | “intramuscular administration” NCT06625541 ↗ |